Moxonidine + Perindopril in Hypertensive Patients With Metabolic Syndrome

NCT ID: NCT04023565

Last Updated: 2019-07-23

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE4
• Total Enrollment: 120 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-03-11
• Study Completion Date: 2020-12-30

Brief Summary

The aim of study is to assess the angioprotective effects of antihypertensive combination therapy with perindopril 10 mg and moxonidine 0.4-0.6 mg in patients with arterial hypertension, metabolic syndrome, and obesity, who had Pulse Wave Velocity (PWV) > 10 m/s on the previously administered two-component combination antihypertensive therapy.

Open-label non-comparative prospective study for 24 week for each patient.

Detailed Description

According to European Society of Cardiology (ESC) and the European Society of Hypertension (ESH) Guidelines for the management of arterial hypertension 2018 in case of previous combination at full dose does not allow to achieve the target Blood Pressure (BP), that therapy might be switch to different two-drug combination.

The study will enroll 120 hypertensive (Grade 1, 2 Arterial Hypertension (AH): Systolic Blood Pressure (SBP) 140-179 mm Hg and Diastolic Blood Pressure (DBP) 90-109 mm Hg According to ESC/ESH Guidelines 2018) patients with metabolic syndrome who met the inclusion criteria when treated with Angiotensin Converting Enzyme Inhibition(ACEi) /Angiotensin Receptor Blocker (ARB) + hydrochlorothiazide (HCTZ)/indapamide or +amlodipine (30 patients in each group):

1. ACEi (except perindopril) + diuretic (HCTZ or indapamide)

2. ACEi (except perindopril) + amlodipine

3. ARB+ diuretic (HCTZ or indapamide)

4. ARB+ amlodipine

Upon obtaining Inform Consent the previous therapy will be discontinued according to recommendations (gradually or at once).

After 14 days of wash-out period perindopril 10 mg + moxonidine 0.4 mg a day will be prescribed.

If target BP is not achieved after 4 weeks, the dosage will increase up to perindopril 10 mg + moxonidine 0.6 mg a day (given as two divided doses).

FORBIDDEN TREATMENTS:

Any other antihypertensives (calcium antagonists, β-blockers, ACEi except perindopril, ARBs, diuretics) for routine AH management (except those used to resolve the uncontrolled hypertension).

CRITERIA FOR PREMATURE PATIENT WITHDRAWAL FROM THE STUDY:

1. Withdrawal of informed consent by the patient at any time of the study.

2. Need for uncontrolled hypertension management occurring more than 2 times weekly throughout the 2 consecutive weeks during study period.

3. Need for the third antihypertensive drug.

Conditions

Arterial Hypertension; Metabolic Syndrome

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

perindopril + moxonidine

perindopril 10 mg + moxonidine 0.4 or 0.6 mg a day (given as two divided doses).

Group Type: EXPERIMENTAL

perindopril + moxonidine

Intervention Type: DRUG

After 14 days of wash-out period perindopril 10 mg + moxonidine 0.4 mg a day will be prescribed.

If target BP is achieved after 4 weeks, the dosage will remain unchanged (perindopril 10 mg + moxonidine 0.4 mg a day (given as two divided doses).

If target BP is not achieved after 4 weeks, the dosage will increase up to perindopril 10 mg + moxonidine 0.6 mg a day (given as two divided doses).

Interventions

perindopril + moxonidine

After 14 days of wash-out period perindopril 10 mg + moxonidine 0.4 mg a day will be prescribed.

If target BP is achieved after 4 weeks, the dosage will remain unchanged (perindopril 10 mg + moxonidine 0.4 mg a day (given as two divided doses).

If target BP is not achieved after 4 weeks, the dosage will increase up to perindopril 10 mg + moxonidine 0.6 mg a day (given as two divided doses).

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Patients (male and female) aging 18 to 70 years.

2. Grade 1, 2 AH (SBP 140-179 mm Hg and/or DBP 90-109 mm Hg according 2018 ESH/ESC guidelines)

3. PWV > 10 m/s

4. Previous two-component antihypertensive therapy (ACEi/ARB+ diuretic (HCTZ or indapamide) or ACEI/ARB + amlodipine) during at least 6 months prior to the study enrollment

5. Metabolic syndrome diagnosed by the 2009 Russian Society of Cardiology (RSC) National Guidelines criteria

1. THE MAIN SIGN: central (abdominal) obesity defined as waist circumference (WC) above 80 cm in women and above 94 cm in men.

2. ADDITIONAL CRITERIA:

i. - arterial hypertension (BP ≥ 130/85 mm Hg) ii. - high triglycerides (≥ 1.7 mmol/l) iii. - decreased HDL-cholesterol (<1.0 mmol/l for men; <1.2 mmol/l for women) iv. - increased LDL-cholesterol > 3.0 mmol/l v. - fasting hyperglycaemia (fasting plasma glucose ≥ 6.1 mmol/l) vi. - impaired glucose tolerance (plasma glucose at 2 hours after glucose load from ≥7.8 to ≤11.1 mmol/l)

Metabolic syndrome is defined as presence of central obesity and two of the additional criteria.

6. Body Mass Index (BMI) >30 kg/m2.

7. For female patients with childbearing potential: negative pregnancy test and willingness to use reliable methods of contraception until the study treatment completion

8. Voluntarily signed informed consent to participate in the study.

Exclusion Criteria

1. Contraindications for using ACEi and imidazoline receptor agonists.

2. Administration of perindopril or moxonidine during 6 months before the study onset.

3. Metformin therapy for prophylaxis diabetes mellitus type 2 in patients with pre-diabetes, which had been started within 6 months before the study enrollment. (If a patient receives metformin for a long time, i.e., more than 6 months, he/she can be included in the study, and metformin discontinuation is not required).

4. Statin and/or fibrate therapy started within 6 months before the study enrollment. (If a patient receives statins and/or fibrates for a long time, i.e., more than 6 months, he/she can be included in the study, and discontinuation of statins and fibrates is not required).

5. Current diagnosis of unstable angina, acute and subacute myocardial infarction.

6. Heart failure of any functional class.

7. Grade 3 AH (≥ 180/110 mm Hg).

8. Sinus bradycardia (heart rate ≤50/min).

9. Type 1 or 2 diabetes mellitus.

10. Severe comorbidities, including mental diseases.

11. Acute conditions (infections, exacerbation of chronic diseases, injuries, surgical interventions).

12. Alcohol abuse.

13. Pregnancy and lactation.

14. Serious renal dysfunction (Estimated Glomerular Filtration Rate (eGFR) by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) ≤30 ml/min/1.73 m2).

15. Serious hepatic dysfunction

16. Malignancies diagnosed and treated during the previous 5 years prior to study enrollment.

17. Inability to understand the study and to give informed consent for participation in it.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sergey V. Nedogoda

OTHER

Sponsor Role: lead

Responsible Party

Sergey V. Nedogoda

Dr.Med.Sc., Professor

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Sergey V. Nedogoda, Professor

Role: PRINCIPAL_INVESTIGATOR

Volgograd State Medical University

Locations

Dept. of Therapy and Endocrinology

Volgograd, , Russia

Site Status: RECRUITING

Countries

Russia

Central Contacts

Sergey V. Nedogoda, Professor

Role: CONTACT

nedogodasv@rambler.ru

+79023643226

Facility Contacts

Sergey V. Nedogoda, Professor

Role: primary

nedogodasv@rambler.ru

+79023643226

Other Identifiers

MOXOD001

Identifier Type: -

Identifier Source: org_study_id